AMIRSYS® Announces PathIQ® ImmunoQuery® Update
AMIRSYS, INC. announced today the update of its PathIQ ImmunoQuery product for pathologists.
Salt Lake City, UT (PRWEB) March 18, 2012
AMIRSYS, INC. announced today the update of its PathIQ ImmunoQuery product for pathologists. This update adds the latest and most important references to the expert and evidence-based decision support system for immunohistochemistry representing over 24,500 cases. Carefully selected by Dr. Dennis Frisman and Dr. Elizabeth Hammond, these updates add 125 new antibody classes, and 229 new diagnoses.
“We are constantly tracking the rapid advancements in the science of immunohistochemistry and updating ImmunoQuery quickly. While many of the antibodies are not new, their expression in a larger number of diagnoses is new” says Dr. Hammond. “For example, there are new articles describing the expression of RCC, TFF-1, PTHR, Podoplanin, p63, and CD117 (C-KIT) in a large number of diagnoses.”
In addition, some new references are related to the thresholds for proliferation potential. “For example, Ki-67, a marker of proliferation, has become critical for the evaluation of malignant potential of various tumors”, adds Dr. Frisman.
Amirsys, Inc. is a leading provider of innovative healthcare solutions in radiology and pathology for physician education and diagnostic decision support. Through use of its proprietary technology and image-intensive, expert-based content, Amirsys provides online problem-solving access to thousands of radiologists and pathologists worldwide. Amirsys’ team of over 300 leading radiologist and pathologist authors develop content which is tagged and stored in its patented ACRES™ authoring system. By utilizing its proprietary technology in combination with its unique content database, Amirsys has produced innovative products that dominate their respective markets.
Contact: Julia Sherman, 949-348-2208, ext. 2101
For more information please visit the Amirsys websites at amirsys.com, statdx.com, and radprimer.com
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/3/prweb9290898.htm